Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Bladder Cancer

 

DN24-02 for High Risk HER2+ Urothelial Carcinoma (Dendreon Neuvenge)
A Randomized, Phase 2, Open-label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma

Investigator: Celestia S. Higano, MD;   Conditions: Urothelial Carcinoma;    Status: Recruiting;   Study ID: NCT01353222

Radiation Therapy + Chemotherapy for Stage T1 Bladder Cancer (UW 7684)
RTOG 0926 A Phase II Protocol For Patients With Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment By Radiation Therapy Concurrent With Radiosensitizing Chemotherapy Following a Thorough Transurethral Surgical Re-Staging.

Investigator: George Laramore, MD, PhD;   Conditions: Bladder Cancer;    Status: Recruiting;   Study ID: NCT00981656

MK-3475 for Advanced Solid Tumors
A Phase Ib Multi-Cohort Study of MK-3475 in Subjects With Advanced Solid Tumors

Investigator: Laura Q.M. Chow, MD;   Conditions: Advanced Solid Tumors;    Status: Closed;   Study ID: NCT01848834

Sirolimus + Cisplatin/Gemcitabine for Bladder Cancer (8027)
A Phase 1-2 Study of Rapamycin (Sirolimus) and Cisplatin/Gemcitabine for Treatment of Patients With Bladder Cancer

Investigator: Bruce Montgomery, MD;   Conditions: Bladder Cancer;    Status: Recruiting;   Study ID: NCT01938573

AGS15E for Metastatic Urothelial Cancer
A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer

Investigator: Evan Ya-Wen Yu, MD;   Conditions: Metastatic Urothelial Cancer;    Status: Recruiting;   Study ID: NCT01963052